Roman Butler Fullerton & CO Neurocrine Biosciences Inc Transaction History

Roman Butler Fullerton & CO

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 31, 2024	BUY	$106.07 - $132.76 $937,340 - $1.17 Million	8,837 New	8,837 $1.16 Million
Q4 2022 Jan 23, 2023	BUY	$106.72 - $127.06 $139,269 - $165,813	1,305 Added 12.36%	11,864 $0
Q3 2022 Oct 17, 2022	BUY	$92.03 - $107.81 $971,744 - $1.14 Million	10,559 New	10,559 $1.14 Million
Q3 2020 Oct 15, 2020	SELL	$96.16 - $135.15 $713,699 - $1 Million	-7,422 Closed	0 $0
Q2 2020 Jul 28, 2020	BUY	$85.09 - $130.36 $631,537 - $967,531	7,422 New	7,422 $905,000

624

94.2M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $11.8B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Roman Butler Fullerton & CO, based on Form 13F filings with the SEC.

Stay updated on Roman Butler Fullerton & CO with notifications on news.